|
1
|
Chandra HS, Heisterkamp NC, Hungerford A,
Morrissette JJ, Nowell PC, Rowley JD and Testa JR: Philadelphia
Chromosome Symposium: commemoration of the 50th anniversary of the
discovery of the Ph chromosome. Cancer Genet. 204:171–179. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deininger MW, Goldman JM and Melo JV: The
molecular biology of chronic myeloid leukemia. Blood. 96:3343–3356.
2000.PubMed/NCBI
|
|
3
|
Hantschel O and Superti-Furga G:
Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol
Cell Biol. 5:33–44. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sattler M and Griffin JD: Molecular
mechanisms of transformation by the BCR-ABL oncogene. Semin
Hematol. 40(Suppl 2): S4–S10. 2003. View Article : Google Scholar
|
|
5
|
Barrett D, Brown VI, Grupp SA and Teachey
DT: Targeting the PI3K/AKT/mTOR signaling axis in children with
hematologic malignancies. Paediatr Drugs. 14:299–316.
2012.PubMed/NCBI
|
|
6
|
Horita M, Andreu EJ, Benito A, Arbona C,
Sanz C, Benet I, et al: Blockade of the Bcr-Abl kinase activity
induces apoptosis of chronic myelogenous leukemia cells by
suppressing signal transducer and activator of transcription
5-dependent expression of Bcl-xL. J Exp Med. 191:977–984. 2000.
View Article : Google Scholar
|
|
7
|
Pene-Dumitrescu T and Smithgall TE:
Expression of a Src family kinase in chronic myelogenous leukemia
cells induces resistance to imatinib in a kinase-dependent manner.
J Biol Chem. 285:21446–21457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baum KJ and Ren R: Effect of Ras
inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol
Oncol. 1:52008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Notari M, Neviani P, Santhanam R, Blaser
BW, Chang JS, Galietta A, et al: A MAPK/HNRPK pathway controls
BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Blood. 107:2507–2516. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baran Y and Saydam G: Cumulative clinical
experience from a decade of use: imatinib as first-line treatment
of chronic myeloid leukemia. J Blood Med. 3:139–150. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mauro MJ and Deininger MW: Chronic myeloid
leukemia in 2006: a perspective. Haematologica.
91:1522006.PubMed/NCBI
|
|
12
|
Shah NP and Sawyers CL: Mechanisms of
resistance to STI571 in Philadelphia chromosome-associated
leukemias. Oncogene. 22:7389–7395. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sawyers CL, Hochhaus A, Feldman E, Goldman
JM, Miller CB, Ottmann OG, et al: Imatinib induces hematologic and
cytogenetic responses in patients with chronic myelogenous leukemia
in myeloid blast crisis: results of a phase II study. Blood.
99:3530–3539. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soleas GJ, Diamandis EP and Goldberg DM:
Resveratrol: a molecule whose time has come? And gone? Clin
Biochem. 30:91–113. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jang DS, Kang BS, Ryu SY, Chang IM, Min KR
and Kim Y: Inhibitory effects of resveratrol analogs on unopsonized
zymosan-induced oxygen radical production. Biochem Pharmacol.
57:705–712. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inoue H, Jiang XF, Katayama T, Osada S,
Umesono K and Namura S: Brain protection by resveratrol and
fenofibrate against stroke requires peroxisome
proliferator-activated receptor alpha in mice. Neurosci Lett.
352:203–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu W, Fu YC and Wang W: Cellular and
molecular effects of resveratrol in health and disease. J Cell
Biochem. 113:752–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Delmas D, Solary E and Latruffe N:
Resveratrol, a phytochemical inducer of multiple cell death
pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med
Chem. 18:1100–1121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tinhofer I, Bernhard D, Senfter M, Anether
G, Loeffler M, Kroemer G, et al: Resveratrol, a tumor-suppressive
compound from grapes, induces apoptosis via a novel mitochondrial
pathway controlled by Bcl-2. FASEB J. 15:1613–1615. 2001.PubMed/NCBI
|
|
20
|
Mgbonyebi OP, Russo J and Russo IH:
Antiproliferative effect of synthetic resveratrol on human breast
epithelial cells. Int J Oncol. 12:865–869. 1998.PubMed/NCBI
|
|
21
|
Ahmad N, Adhami VM, Afaq F, Feyes DK and
Mukhtar H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest
of cell cycle and induction of apoptosis in human epidermoid
carcinoma A431 cells. Clin Cancer Res. 7:1466–1473. 2001.PubMed/NCBI
|
|
22
|
Dörrie J, Gerauer H, Wachter Y and Zunino
SJ: Resveratrol induces extensive apoptosis by depolarizing
mitochondrial membranes and activating caspase-9 in acute
lymphoblastic leukemia cells. Cancer Res. 61:4731–4739. 2001.
|
|
23
|
Benitez DA, Pozo-Guisado E,
Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA:
Mechanisms involved in resveratrol-induced apoptosis and cell cycle
arrest in prostate cancer-derived cell lines. J Androl. 28:282–293.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fulda S and Debatin KM:
Resveratrol-mediated sensitisation to TRAIL-induced apoptosis
depends on death receptor and mitochondrial signalling. Eur J
Cancer. 41:786–798. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shankar S, Siddiqui I and Srivastava RK:
Molecular mechanisms of resveratrol
(3,4,5-trihydroxy-trans-stilbene) and its interaction with
TNF-related apoptosis inducing ligand (TRAIL) in
androgen-insensitive prostate cancer cells. Mol Cell Biochem.
304:273–285. 2007. View Article : Google Scholar
|
|
26
|
Shankar S, Singh G and Srivastava RK:
Chemoprevention by resveratrol: molecular mechanisms and
therapeutic potential. Front Biosci. 12:4839–4854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang H, Zhang L, Kuo J, Kuo K, Gautam SC,
Croc L, et al: Resveratrol-induced apoptotic death in human U251
glioma cells. Mol Cancer Ther. 4:554–561. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang H, Shang X, Wu H, Gautam SC,
Al-Holou S, Li C, et al: Resveratrol downregulates PI3K/Akt/mTOR
signaling pathways in human U251 glioma cells. J Exp Ther Oncol.
8:25–33. 2009.PubMed/NCBI
|
|
29
|
Yang CS, Landau JM, Huang MT and Newmark
HL: Inhibition of carcinogenesis by dietary polyphenolic compounds.
Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quoc Trung L, Espinoza JL, Takami A and
Nakao S: Resveratrol induces cell cycle arrest and apoptosis in
malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One.
8:e551832013.PubMed/NCBI
|
|
31
|
Miki H, Uehara N, Kimura A, Sasaki T, Yuri
T, Yoshizawa K and Tsubura A: Resveratrol induces apoptosis via
ROS-triggered autophagy in human colon cancer cells. Int J Oncol.
40:1020–1028. 2012.PubMed/NCBI
|
|
32
|
Hussain AR, Uddin S, Bu R, Khan OS, Ahmed
SO, Ahmed M and Al-Kuraya KS: Resveratrol suppresses constitutive
activation of AKT via generation of ROS and induces apoptosis in
diffuse large B cell lymphoma cell lines. PLoS One. 6:e247032011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Truong M, Cook MR, Pinchot SN,
Kunnimalaiyaan M and Chen H: Resveratrol induces Notch2-mediated
apoptosis and suppression of neuroendocrine markers in medullary
thyroid cancer. Ann Surg Oncol. 18:1506–1511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Q, Ganapathy S, Singh KP, Shankar S
and Srivastava RK: Resveratrol induces growth arrest and apoptosis
through activation of FOXO transcription factors in prostate cancer
cells. PLoS One. 5:e152882010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leong CW, Wong CH, Lao SC, Leong EC, Lao
IF, Law PT, et al: Effect of resveratrol on proliferation and
differentiation of embryonic cardiomyoblasts. Biochem Biophys Res
Commun. 360:173–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaminski J, Lançon A, Aires V, Limagne E,
Tili E, Michaille JJ and Latruffe N: Resveratrol initiates
differentiation of mouse skeletal muscle-derived C2C12 myoblasts.
Biochem Pharmacol. 84:1251–1259. 2012. View Article : Google Scholar
|
|
37
|
Yu XM, Jaskula-Sztul R, Ahmed K, Harrison
AD, Kunnimalaiyaan M and Chen H: Resveratrol induces
differentiation markers expression in anaplastic thyroid carcinoma
via activation of Notch1 signaling and suppresses cell growth. Mol
Cancer Ther. 12:1276–1287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yap TA, Garrett MD, Walton MI, Raynaud F,
de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway:
progress, pitfalls, and promises. Curr Opin Pharmacol. 8:393–412.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wetzker R and Rommel C: Phosphoinositide
3-kinases as targets for therapeutic intervention. Curr Pharm Des.
10:1915–1922. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
|
|
42
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene.
22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Martelli AM, Evangelisti C, Chiarini F,
Grimaldi C, Manzoli L and McCubrey JA: Targeting the PI3K/AKT/mTOR
signaling network in acute myelogenous leukemia. Expert Opin
Investig Drugs. 18:1333–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao N, Zhang Z, Jiang BH and Shi X: Role
of PI3K/AKT/mTOR signaling in the cell cycle progression of human
prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun C, Hu Y, Liu X, Wu T, Wang Y, He W and
Wei W: Resveratrol downregulates the constitutional activation of
nuclear factor-kappaB in multiple myeloma cells, leading to
suppression of proliferation and invasion, arrest of cell cycle,
and induction of apoptosis. Cancer Genet Cytogenet. 165:9–19. 2006.
View Article : Google Scholar
|
